
News|Articles|March 1, 2002
Eligard 7.5 mg (Leuprolide acetate 7.5 mg for subcutaneous injection), Atrix/Sanofi-Synthelabo
New formulation: Monthly SC injection form of GnRH agonist for advanced prostate cancer
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The FDA proposes ditching comparative efficacy studies for biosimilars
2
Atopic dermatitis care advances in 2025 with new biologics, topicals and oral therapies
3
Misdiagnosis of Type 1 diabetes remains a major problem, despite advances
4
UC Davis develops new drug for bladder cancer patients
5


















































